| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G/A
| WASATCH ADVISORS LP reports a 10.2% stake in Sangamo Therapeutics, Inc. |
| 09/28/2023 |
4
| BIOGEN INC. (10% Owner) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Sold 6,000,000 shares
@ $0.5, valued at
$3M
|
|
| 08/15/2023 |
4
| Willoughby Scott B. (SVP, Gen. Counsel & Secretary) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 864 shares
@ $1.08, valued at
$933.1 |
|
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/05/2023 |
4
| Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| PARKER H STEWART (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| Meyers James R (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| Markels John (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| Horn Margaret A (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| Hillan Kenneth J. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| Carey Robert (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/05/2023 |
4
| Beers Courtney (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 06/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/30/2023 |
4
| Willoughby Scott B. (SVP, Gen. Counsel & Secretary) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 1,328 shares
@ $1.33, valued at
$1.8k
|
|
| 05/30/2023 |
4
| Ramelmeier Rolf Andrew (EVP, Technical Operations) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 1,750 shares
@ $1.33, valued at
$2.3k
|
|
| 05/30/2023 |
4
| McClung David Mark (EVP, COO) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 1,925 shares
@ $1.33, valued at
$2.6k
|
|
| 05/30/2023 |
4
| Dubois-Stringfellow Nathalie (SVP-Chief Development Officer) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 1,462 shares
@ $1.33, valued at
$1.9k
|
|
| 05/30/2023 |
4
| Fontenot Jason D. (SVP, Chief Scientific Officer) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 1,029 shares
@ $1.33, valued at
$1.4k
|
|
| 05/30/2023 |
4
| Duraibabu Prathyusha (SVP, CFO) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 1,328 shares
@ $1.33, valued at
$1.8k
|
|
| 05/30/2023 |
4
| Macrae Sandy (President, CEO and Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Paid exercise price by delivering 10,411 shares
@ $1.33, valued at
$13.8k
|
|
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/17/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/17/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 03/14/2023 |
8-K
| Other Events Interactive Data |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
|